Literature DB >> 12740298

Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients.

Steven D Nathan1, Scott D Barnett, Bruce A Urban, Cynthia Nowalk, Brian R Moran, Nelson Burton.   

Abstract

The objectives of the study were the assessment of the incidence of pulmonary embolism (PE) in lung transplant recipients. We performed a retrospective review of the medical records in a tertiary center lung transplant program. A total of 72 lung transplants were performed. There were seven symptomatic PE events diagnosed among six patients (group 1). All PE events were in the subgroup of patients with idiopathic pulmonary fibrosis (IPF) [6 of 23 patients (27%) vs 0 among all other patients (0%); p < 0.001]. All patients were out of the hospital, not receiving oxygen therapy, and were ambulatory at the time of the event. The median time to occurrence of the PE was 175 days posttransplant (range, 26 to 541 days). All patients who developed PEs were men. The group of IPF patients with no PEs was evenly split between genders (group 2; p < 0.009). PE patients required a longer posttransplant hospitalization (mean [+/- SD], 18.5 +/- 3.9 vs 13.5 +/- 4 days, respectively; p < 0.018). Aside from this, there was no apparent difference in patient functional status between the two groups. PEs appear to be relatively common in IPF lung transplant recipients. This should be considered in the differential diagnosis of any such patient who presents with dyspnea or hypoxia posttransplant. Patients do not appear to have been predisposed to their embolic events through lack of activity or prolonged hospital stays.

Entities:  

Mesh:

Year:  2003        PMID: 12740298     DOI: 10.1378/chest.123.5.1758

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.

Authors:  Jonathan P Singer; Meng-Yu Huang; Christine Hui; Paul D Blanc; Rebecca F Boettger; Jeffery Golden; Katherine Watkins; Charles Hoopes; Lorriana E Leard
Journal:  J Heart Lung Transplant       Date:  2010-06-08       Impact factor: 10.247

Review 2.  High-resolution CT of complications of idiopathic fibrotic lung disease.

Authors:  C R Lloyd; S L F Walsh; D M Hansell
Journal:  Br J Radiol       Date:  2011-07       Impact factor: 3.039

3.  Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation.

Authors:  Joseph L Bobadilla; Robert B Love; Ewa Jankowska-Gan; Qingyong Xu; Lynn D Haynes; Ruedi K Braun; Mary S Hayney; Alejandro Munoz del Rio; Keith Meyer; Daniel S Greenspan; Jose Torrealba; Kathleen M Heidler; Oscar W Cummings; Takekazu Iwata; David Brand; Robert Presson; William J Burlingham; David S Wilkes
Journal:  Am J Respir Crit Care Med       Date:  2008-01-03       Impact factor: 21.405

4.  Venous Thromboembolism After Adult Lung Transplantation: A Frequent Event Associated With Lower Survival.

Authors:  Manuel L Ribeiro Neto; Marie Budev; Daniel A Culver; C Randall Lane; Marcelo Gomes; Xiao-Feng Wang; Paulo Novis Rocha; Mitchell A Olman
Journal:  Transplantation       Date:  2018-04       Impact factor: 4.939

Review 5.  Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature.

Authors:  Kristin D Kistler; Luba Nalysnyk; Philip Rotella; Dirk Esser
Journal:  BMC Pulm Med       Date:  2014-08-16       Impact factor: 3.317

Review 6.  Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management.

Authors:  Fabrizio Luppi; Meena Kalluri; Paola Faverio; Michael Kreuter; Giovanni Ferrara
Journal:  Respir Res       Date:  2021-04-17

Review 7.  The Management of Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Paolo Spagnolo; Argyris Tzouvelekis; Francesco Bonella
Journal:  Front Med (Lausanne)       Date:  2018-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.